Skip to main content
Multiple Sclerosis Discovery Forum
User Top Menu
Who We Are
How to Cite
News & Future Directions
Essays & Opinions
Meetings & Events
Clinical Trials - Public Availability of Results
MS trials baseline
Map of MS Prevalence
Progressive MS Authors Galaxy
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Scientific Literature TreeMap
Clinical Trials in MS
Click Here to Support MSDF
You are here
Most Viewed Papers
Immunosuppressive properties of mesenchymal stem cells: advances and applications.
Phase II study of oral masitinib mesilate in imatinib-naïve patients with locally advanced or metastatic gastro-intestinal stromal tumour (GIST).
Suppressed RNA-Polymerase 1 Pathway Is Associated with Benign Multiple Sclerosis.
Masitinib in Patients with Primary Progressive Multiple Sclerosis (PPMS) or Relapse-Free Secondary Multiple Sclerosis (SPMS)
Extra-Gastrointestinal Manifestations of Inflammatory Bowel Disease May Be Less Common Than Previously Reported.
The Role of Medicinal Cannabis in Clinical Therapy: Pharmacists' Perspectives.
Mucocele After Orbital Fracture Repair Masquerading as Optic Neuritis.
Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial.
Neuromyelitis optica study model based on chronic infusion of autoantibodies in rat cerebrospinal fluid.
Protective Effects of PGC-1α via the Mitochondrial Pathway in Rat Brains after Intracerebral Hemorrhage.
Susac's syndrome: Leptomeningeal enhancement on 3D FLAIR MRI.
Immunomodulators and immunosuppressants for multiple sclerosis: a network meta-analysis.
Rebound Syndrome in Patients With Multiple Sclerosis After Cessation of Fingolimod Treatment.
New diagnostic criteria for multiple sclerosis: guidelines for research protocols.
Phase II Study with Ocrelizumab Shows Significant Reduction in Disease Activity for Multiple Sclerosis Patients
Vitamin D and autoimmunity.
Potassium channel KIR4.1 as an immune target in multiple sclerosis.
The Characteristics of Multiple Sclerosis in Iran.
Comparison of Relapse and Treatment Failure Rates Among Patients With Neuromyelitis Optica: Multicenter Study of Treatment Efficacy.
Gender as risk factor for autoimmune diseases.
Astrocyte tissue factor controls CNS hemostasis and autoimmune inflammation.
BG 12: BG 00012, BG 12/Oral Fumarate, FAG-201, second-generation fumarate derivative--Fumapharm/Biogen Idec.
Drug-based modulation of endogenous stem cells promotes functional remyelination in vivo.
Consent guidance: patients and doctors making decisions together
Gender-specific expression of beta1 integrin of VLA-4 in myelin basic protein-primed T cells: implications for gender bias in multiple sclerosis.